Article tools
Author information

Articles

Immunologic responses to bacteriophage ϕX 174 in immunodeficiency diseases

Hans D. Ochs, Starkey D. Davis and Ralph J. Wedgwood

1Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195

Published December, 1971

Immunologic responses to bacteriophage ϕX 174 were studied in 26 patients with immunodeficiency diseases. In eight cases of infantile X-linked agammaglobulinemia, there was prolonged circulation of phage and no detectable antibody response. The remaining 18 patients cleared phage normally and produced antibodies. 10 of these patients made only IgM antibody in spite of repeated immunization; all of these have recurrent respiratory tract infections and require treatment with gamma globulin and antibiotics. Eight patients made both IgM and IgG antibody; they experience either milder or no infections, and only one requires treatment with gamma globulin.

Prolonged circulation of bacteriophage ϕX 174 and the absence of a detectable antibody response appear to be distinguishing characteristics of X-linked agammaglobulinemia if severe combined immunodeficiency can be excluded.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Articles that cite
this article:

Biological Gene Delivery Vehicles: Beyond Viral Vectors
Yiqi Seow, Matthew J Wood
Mol Ther 17(5):767. [CrossRef]

The role of costimulation in antibody deficiencies: ICOS and common variable immunodeficiency
Patrick F. K. Yong, Ulrich Salzer, Bodo Grimbacher
Immunol Rev 229(1):101. [CrossRef]

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Judith R. Abrams, Mark G. Lebwohl, Cynthia A. Guzzo, Brian V. Jegasothy, Michael T. Goldfarb, Bernard S. Goffe, Alan Menter, Nicholas J. Lowe, Gerald Krueger, Michael J. Brown
J Clin Invest 103(9):1243. [CrossRef]

Bacteriophage biocontrol in animals and meat products
R. J. Atterbury
Microbial Biotech 2(6):601. [CrossRef]

Selective targeting of T cell subsets: focus on alefacept – a remittive therapy for psoriasis
Gerald G Krueger
ebot 2(4):431. [CrossRef]

Management of Patients with Primary Immune Deficiency Syndromes
J. Vivian Wells, H. Hugh Fudenberg
Intern Med J 4(4):396. [CrossRef]

In vivo chromosomal instability in ataxia-telangiectasia homozygotes and heterozygotes
Miriam P. Rosin, H. D. Ochs
Hum Genet 74(4):335. [CrossRef]

The antibody response to bacteriophage is linked to the lymphopenia gene in congenic BioBreeding rats
Leila Clark, Carla Greenbaum, Jianjie Jiang, Ake Lernmark, Hans Ochs
FEMS Immunol Med Microbiol 32(3):205. [CrossRef]

Defective surface expression of attractin on T cells in patients with common variable immunodeficiency (CVID)
N. Pozzi, L. Gaetaniello, B. Martire, D. De mattia, B. Balestrieri, E. Cosentini, S. F. Schlossman, J. S. Duke-cohan, C. Pignata
Clin Exp Immunol 123(1):99. [CrossRef]

Graft-versus-Host Reactions and Disease
G. W. Santos, A. D. Hess, G. B. Vogelsan
Immunol Rev 88(1):169. [CrossRef]

Graft-versus-Host-Reactions: The History that never Was, and the Way Things Happened to Happen
Morten Simonsen
Immunol Rev 88(1):5. [CrossRef]

The molecular basis for T cell help in humoral immunity: CD40 and its ligand, gp39
Lisa S. Marshall, Alejandro Aruffo, Jeffrey A. Ledbetter, Randolph J. Noelle
J Clin Immunol 13(3):165. [CrossRef]

Rituximab Inhibits the In Vivo Primary and Secondary Antibody Response to a Neoantigen, Bacteriophage phiX174
Christopher M. Bearden, Avinash Agarwal, Benita K. Book, Carlos A. Vieira, Richard A. Sidner, Hans D. Ochs, Marquerite Young, Mark D. Pescovitz
Am J Transplant 5(1):50. [CrossRef]

A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1)
A. Repik, S. E. Pincus, I. Ghiran, A. Nicholson-weller, D. R. Asher, A. M. Cerny, L. S. Casey, S. M. Jones, S. N. Jones, N. Mohamed
Clin Exp Immunol 140(2):230. [CrossRef]

Evaluation of families wherein a single male manifests a phenotype of X-linked lymphoproliferative disease (XLP)
Helen L. Grierson, James Skare, Joseph Church, Teresa Silberman, Jack R Davis, Nathan Kobrinsky, Rebert Mcgregor, Sara Israels, James Mccarty, Lucy G. Andrews
Am J Med Genet 47(4):458. [CrossRef]

Diminished expression of CD40 ligand may contribute to the defective humoral immunity in patients with MHC class II deficiency
Shigeaki Nonoyama, Amos Etzioni, Hano Toru, Dennis P. Ruggerie, David Lewis, Shimon Pollack, Alejandro Aruffo, Jun-Ichi Yata, Hans D. Ochs
Eur J Immunol 28(2):589. [CrossRef]

A new RFLP marker, SP282, at thebtk locus for genetic analysis in X-linked agammaglobulinaemia families
Sau-Ping Kwan, Ann P. Walker, Tracy Hagemann, Sudhir Gupta, Bharathi Vayuvegula, Hans D. Ochs
Prenat Diagn 14(6):493. [CrossRef]

Epstein-Barr???associated Leiomyomatosis and T-cell Chimerism After Haploidentical Bone Marrow Transplantation for Severe Combined Immunodeficiency Disease
Srilatha Atluri, Kathleen Neville, Mary Davis, Kent A. Robertson, Francis E. Marshalleck, Dennis P. O??malley, Rebecca H. Buckley, Robert P. Nelson
J Pediatr Hematol Oncol 29(3):166. [CrossRef]

Intensive postgrafting immune suppression combined with nonmyeloablative conditioning for transplantation of HLA-identical hematopoietic cell grafts: results of a pilot study for treatment of primary immunodeficiency disorders
L M Burroughs, R Storb, W M Leisenring, M A Pulsipher, M R Loken, T R Torgerson, H D Ochs, A E Woolfrey
J Hum Hypertens 40(7):633. [CrossRef]

Effect of Therapeutic Integrin (CD11a) Blockade with Efalizumab on Immune Responses to Model Antigens in Humans: Results of a Randomized, Single Blind Study
James G Krueger, Hans D Ochs, Piyush Patel, Ellen Gilkerson, Emma Guttman-yassky, Wolfgang Dummer
J Invest Dermatol 128(11):2615. [CrossRef]

Immunologic Disorders: The Regulation of Humoral Immunity
Hans D. Ochs, Ralph J. Wedgwood
Vox Sang [CrossRef]